Results 241 to 250 of about 61,480 (319)

A drug-drug interaction study to evaluate the effects of strong CYP3A4 inducer on the pharmacokinetics of segesterone acetate and ethinyl estradiol in a contraceptive vaginal system. [PDF]

Contracept Reprod Med
Plagianos M, Lansiaux M, Kumar N, Graham S, Sussman H, Kushner H, Creasy G, Bernick B, Haddad LB.   +8 more
europepmc   +1 more source

L'utilisation de la dompéridone comme substrat marqueur de l'activité in vitro des CYP3A4 et CYP3A5

, 2003
Véronique Michaud
openalex   +2 more sources

Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors

Basic & Clinical Pharmacology & Toxicology, 2015
Stina Betts, L. Björkhem-Bergman, A. Rane, L. Ekström   +3 more
semanticscholar   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

Omeprazole Induces <i>CYP3A4</i> mRNA Expression but Not CYP3A4 Protein Expression in HepaRG Cells

Yuto Fujita, Takahito Miyake, Xinyan Shao, Yuto Aoki, Emi Hasegawa, Masao Doi   +5 more
openalex   +2 more sources

GW4064, an Agonist of Farnesoid X Receptor, Represses CYP3A4 Expression in Human Hepatocytes by Inducing Small Heterodimer Partner Expression

Drug Metabolism And Disposition, 2015
Shu Zhang, Xian Pan, Hyunyoung Jeong
semanticscholar   +1 more source

Risk of opioid overdose associated with concurrent use of hydrocodone and CYP3A4-inhibiting calcium channel blockers: a population-based cohort study. [PDF]

Am J Epidemiol
Bea S, Basham CA, Edrees HH, Huybrechts KF, Vine SM, Glynn RJ, Bateman BT, Bykov K.   +7 more
europepmc   +1 more source

Characterization of midazolam metabolism in locusts: the role of a CYP3A4-like enzyme in the formation of 1′-OH and 4-OH midazolam

, 2015
Line Rørbæk Olsen, Charlotte Gabel‐Jensen, Sileshi Gizachew Wubshet, Kenneth T. Kongstad, Christian Janfelt, Lassina Badolo, Steen Honoré Hansen   +6 more
openalex   +2 more sources

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

The Pharmacogenomics Journal, 2011
Danxin Wang, Y. Guo, S. Wrighton, G. Cooke, W. Sadee   +4 more
semanticscholar   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source